Entrepreneurs, take heart…

Any of you reading this who has ever raised money or been on the road, been involved in business development or sales, will know the feeling I am about to describe. After a very excellent day of meetings in Sydney, mostly around raising some philanthropic funds for a project I am working on, I got to…

Orthosmell

Orthocell (ASX : OCC) has had two ASX “slaps” in the last month, to which the company pleaded “Schultz“. The first involved a bout of trading around the 6th of July. The second, a more detailed price query follow-up including some concerns in relation to activity on/around the 14th of July. Today we saw another…

Clinical Trial Communication Matters

Over the past few months I have poked several companies in the eye for the appalling quality of their clinical communication. I have specifically paid attention to Novogen (ASX : NRT), Benitec (ASX : BLT), Regeneus (ASX : RGS) and a few others. It is my position is that there is a consistently low quality and sensationalist ethos…

Open Letter to Dr. Graham Kelly

Dear Dr. Kelly, For a guy of your purported intelligence and charisma, and alleged grasp of oncology drug development, I am getting a bit tired of your company’s crappy press releases announcing that yet another mouse or two have been “successfully” treated with one of your drugs. Aside from the fact that most self-respecting pharmaceutical companies don’t actually…

Novogen : Unacceptable Behaviour (Part II)

In this continuation of my prior rant about Novogen CEO Graham Kelly’s questionable interactions with shareholders on HotCopper, I want to specifically review each of the “questions” that appeared on HotCopper and perhaps share some perspectives that will help you to understand why I really despise this kind of informal chit-chat. I note that I have…